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Abstract We have recently shown that collagen activates 
platelets through a pathway dependent on the Fc receptor 
y-chain and the tyrosine kinase Syk. We report here that the Fc 
receptor y-chain and the candidate collagen receptor glycoprotein 
VI (GPVI) co-associate. Furthermore, cross-linking GPVI 
stimulates a similar pattern of tyrosine phosphorylation to that 
stimulated by collagen, including tyrosine phosphorylation of Fc 
receptor y-chain. These results support a model where GPVI 
couples collagen-stimulation of platelets to phosphorylation of 
the Fc receptor y-chain leading to activation of Syk and 
phospholipase Cy2. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Collagens are major components of extracellular matrix and 
connective tissue. On damage to the vascular endothelium, 
platelets adhere to newly exposed collagen fibres of the blood 
vessel wall leading to the secretion of various mediators and 
platelet aggregation, contributing to the formation of a hae-
mostatic plug. The size and complex structure of collagen 
gives the potential to bind and consequently cross-link multi-
ple receptors on platelets. Several potential collagen receptors 
on the platelet surface have been proposed. It is generally 
recognised that the integrin a2(3i plays a major role in the 
initial adhesion to collagen, and a growing body of evidence 
supports a second receptor site underlying secretion and ag-
gregation [1-5]. Candidates for this second receptor include 
glycoprotein IV (GPIIIb , CD36) [6], glycoprotein VI [7-10], 
the C l q receptor [11] and uncharacterised 65-kDa [12] and 
85-90-kDa glycoproteins [13]. Activation of platelets by col-
lagens is mediated via a tyrosine kinase-dependent pathway 
resulting in phosphorylation of the FcR y-chain [4,5], the ty-
rosine kinase Syk [4,5,14] and culminates in the phosphoryla-
tion of phospholipase Cy2 (PLCy2) [15,16]. Using genetically 
modified mice we have demonstrated that the FcR y-chain 
and Syk are absolutely required for collagen-stimulated secre-
tion and aggregation and that tyrosine phosphorylation of the 
FcR y-chain lies upstream of Syk, and that Syk lies upstream 
of PLCy2 [5]. Collagen-stimulated signalling in platelets there-
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fore resembles signalling mechanisms induced by immune re-
ceptors such as Fc and antigen receptors [17-20]. This identi-
fies collagen as a unique physiological platelet agonist which 
induces activation through a pathway that was originally 
thought to be used only by immune receptor stimuli. Of the 
proteins proposed as collagen receptors underlying activation 
through a pathway of this kind, an increasing amount of 
evidence favours GPVI . Deficiency in expression of GPVI 
results in impaired aggregation responses to collagen, and 
antibodies which recognise GPVI have been shown to inhibit 
collagen-stimulated aggregation [7,8,10,21]. Cross-linking 
GPVI results in phosphorylation and activation of Syk [9] 
and activation of Syk by collagen is severely compromised 
in platelets which do not express GPVI [22]. It has also 
been reported that under conditions of flow, GPVI contrib-
utes to platelet adhesion to a collagen-coated surface [23]. In 
this report we examine the roles of GPVI and the FcR y-chain 
as components of a multimeric receptor complex which under-
lies collagen-stimulated activation of platelets. 
2. Materials and methods 
2.1. Materials 
Anti-FcR y-chain antiserum [24] was kindly provided by Dr. J.-P. 
Kinet (Beth Israel Hospital, Boston, MA, USA). IgG was extracted 
using protein A-Sepharose from the plasma of a patient with auto-
immune thrombocytopenia and whose serum contains autoantibodies 
specific for GPVI [21]. Control IgG was extracted in the same way 
from normal human plasma. Anti-phosphotyrosine monoclonal anti-
body (mAb) 4G10 was from Upstate Biotechnology (TCS Biologicals 
Ltd., Botolph Claydon, Bucks, UK) and anti-FcyRII mAb IV.3 was 
from Medarex Inc. (Annandale, NJ, USA). Collagen fibres, as Horm 
collagen, a suspension of type I fibres from equine tendon, were ob-
tained from Nycomed (Munich, Germany). Collagen-related peptide 
(CRP: GCP*(GPP*)i0GCP*G; single amino acid code P* = hydroxy-
proline) was synthesised and cross-linked (CRP-XL) as previously 
described [25]. NHS-LC-Biotin was from Pierce and Warriner (Ches-
ter, Cheshire, UK), immobilised pepsin was from Sigma (Poole, Dor-
set, UK) and all other reagents were from previously described sour-
ces [14]. 
2.2. Preparation and stimulation of platelets 
Blood was taken with informed consent from drug-free volunteers. 
Washed platelets were prepared as described previously [14] and sus-
pended in modified Tyrodes-HEPES buffer (134 mM NaCl, 0.34 mM 
Na 2HP0 4 , 2.9 mM KCl, 12 mM NaHCO,,, 20 mM HEPES, 5 mM 
glucose, 1 mM MgCl2, pH 7.3). Platelets were resuspended at densities 
of 2X108 cells/ml and 8 x10 s cells/ml for aggregation and protein 
precipitation studies respectively. Platelets were stimulated at 37°C 
with continuous stirring with collagen (100 Jig/ml, 90 s) or CRP-XL 
(1 ug/ml, 90 s) in the presence of indomethacin (10 uM) and EGTA 
(1 mM), with the exception of the aggregation studies in which these 
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reagents were omitted. Cross-linking of the platelet IgG receptor, 
FcyRIIA, was performed by pre-incubation of platelets for 60 s 
with mAb IV.3 (1 ug/ml) followed by stimulation for 60 s by addition 
of anti-mouse IgG F(ab')2 (30 ug/ml). Where surface labelling of 
platelets was required, platelets isolated from platelet-rich plasma 
were resuspended in 1 ml of a 10 mM solution of the water soluble 
biotinylation reagent sulphosuccinimidyl-6-(biotinamido) hexanoate 
(NHS-LC-Biotin) prepared in modified Tyrodes-HEPES buffer. Pla-
telets were incubated in this buffer for 30 min at 30°C and then 
diluted in modified Tyrodes-HEPES buffer to 25 ml. Platelets were 
pelleted by centrifugation at 1000 Xg for 10 min and resuspended for 
use as described above. 
2.3. Generation of F(ab') g fragments 
IgG solutions were dialysed and concentrated to give 20 mg/ml IgG 
in 20 mM CH3COONa pH 4. To the IgG was added pepsin (250-500 
U) immobilised on agarose which was then mixed for 15 h at 37°C. 
Digestion was terminated by the addition of an equal volume of 
10 mM Tris-HCL pH 7.5, the antibody solution was removed and 
remaining whole antibody and Fc fragments removed by incubation 
with protein-A Sepharose. The purity of the F(ab')2 preparations were 
checked by SDS-PAGE and protein concentration determined using a 
bicinchoninic acid protein assay. 
2.4. GPVI cross-linking studies 
Control and anti-GPVI F(ab')2 fragments were incubated with 
washed platelets for 5 min under stirring conditions and aggregation 
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Fig. 1. The FcR y-chain co-precipitates with a 60-kDa cell-surface 
protein. Tyrosine phosphorylated FcR y-chain was precipitated from 
collagen- (100 ug/ml, 90) and CRP-XL- (1 ug/ml, 90 s) stimulated 
surface-biotinylated platelets using a GST fusion protein containing 
the tandem SH2 domains of Syk. Proteins were separated by SDS-
PAGE, transferred to a PVDF membrane and surface proteins de-
tected by probing with a streptavidin-horseradish peroxidase conju-
gate and developed using an ECL detection system. The position of 
a surface protein of approximately 60 kDa which co-precipitates 
with the FcR y-chain. Similar results were observed in 6 studies. 
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Fig. 2. The FcR y-chain co-associates with GPVI. GPVI was immu-
noprecipitated from lysates from basal or collagen-stimulated 
(100 ug/ml, 90 s) platelets using anti-GPVI IgG (10 ug/ml lysate) ex-
tracted from human plasma. Proteins were separated by SDS-PAGE 
and immunoblotted to detect the FcR y-chain. The position of non-
tyrosine phosphorylated FcR y-chain which co-immunoprecipitates 
with GPVI is shown. Similar results were observed in 4 experi-
ments. 
measured as an increase in optical density. Stimulation was termi-
nated by the addition of Laemmli sample treatment buffer. Proteins 
were separated by SDS-PAGE and immunoblotted for tyrosine phos-
phorylation using mAb 4G10. A GST-fusion protein containing the 
tandem SH2 domains of Syk was prepared, immobilised on agarose 
and used for the precipitation of the FcR y-chain as described pre-
viously [4]. Platelets were stimulated as above and tyrosine phos-
phorylated FcR y-chain precipitated from lysates using GST-Syk 
SH2 fusion protein (10 ug/ml lysate). Proteins were separated by 
SDS-PAGE and immunoblotted for tyrosine phosphorylation. 
2.5. Immunoprecipitation and immunoblotting studies 
Immunoprecipitation and immunoblotting studies were performed 
as described previously [4]. Anti-GPVI IgG was used at a concentra-
tion of 10 ug/ml platelet lysate for immunoprecipitation of GPVI. 
Detection of phosphotyrosine residues was performed using mAb 
4G10 (1 ug/ml) and anti-mouse Ig-horseradish peroxidase conjugated 
secondary antibody used at a dilution of 1:10000. For detection of 
the FcR y-chain, anti-FcR y-chain rabbit antiserum was used diluted 
1:10000 and anti-rabbit Ig-horseradish peroxidase conjugated sec-
ondary antibody used at a dilution of 1:10000. All immunoblots 
were developed using an enhanced chemiluminescence (ECL) detec-
tion system. Platelet surface proteins labelled with biotin were de-
tected on western blots by incubation with a streptavidin-horseradish 
peroxidase conjugate diluted 1:50000 in Tris-buffered saline (20 mM 
Tris, 137 mM NaCl) containing 0.1% (v/v) Tween 20 (TBS-T) and 2% 
(w/v) BSA. Blots were washed in TBS-T for 2 h and developed using 
an ECL detection system. 
3. Results and discussion 
We have shown that the FcR y-chain is essential for colla-
gen-stimulated activation of platelets and have proposed that 
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Fig. 3. Cross-linking GPVI causes tyrosine phosphorylation of the FcR y-chain. (i) Washed platelets were incubated with control or anti-GPVI 
F(ab'>2 fragments (750 |ig/ml) at 37°C under stirring conditions. The level of aggregation was monitored by measuring the increase in optical 
density, (ii) Platelets incubated with control or anti-GPVI F(ab')2 fragments for 150 s or stimulated with collagen (100 U-g/ml, 90 s) were treated 
with Laemmli sample treatment buffer. Following SDS-PAGE and transfer to PVDF membrane, levels of tyrosine phosphorylation were 
assessed by immunoblotting using mAb 4G10. Arrows indicate prominent proteins of 145, 130, 80, 40 and 12 kDa which become tyrosine 
phosphorylated following treatment with anti-GPVI F(ab')2 fragments and collagen-stimulation, (iii) Platelets were incubated with control or 
anti-GPVI F(ab')2 fragments for 150 s and then lysed. Tyrosine phosphorylated FcR y-chain was precipitated from platelet lysates with an im-
mobilised GST fusion protein containing the tandem SH2 domains of Syk. Precipitated proteins were separated by SDS-PAGE and immuno-
blotted to detect phosphotyrosine residues using mAb 4G10. Results are representative of 2 separate experiments. 
this protein may be associated with the collagen receptor 
which underlies platelet activation. To examine this, tyrosine 
phosphorylated FcR y-chain was precipitated from lysates 
from biotin surface-labelled platelets using a GST fusion pro-
tein containing the tandem SH2 domains of Syk a described 
previously [4]. Co-associated surface proteins were detected on 
western blots by probing for biotin. Fig. 1 shows that stim-
ulation with collagen or CRP-XL leads to an increase in the 
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level of tyrosine phosphorylation and precipitation of the FcR 
y-chain and co-precipitation of a membrane protein with a 
molecular mass of approximately 60 kDa. This protein mi-
grates on reducing SDS-PAGE to a similar position to GPVI. 
The interaction of GPVI with the FcR y-chain was exam-
ined further by immunoprecipitation of GPVI. Proteins were 
separated by SDS-PAGE and immunoblotted to detect the 
FcR y-chain. Fig. 2 shows the presence of a similar level of 
the FcR y-chain in GPVI immunoprecipitates under basal and 
collagen-stimulated conditions. This suggests that GPVI and 
the FcR y-chain co-associate in the collagen receptor complex. 
Tyrosine phoshorylated FcR y-chain is distinguished from the 
non-phosphorylated form due to a shift in migration on SDS-
PAGE under reducing conditions from an apparent molecular 
weight of 6-8 kDa to 12 kDa. However, collagen-stimulation 
results in only a small proportion of the total cellular FcR 
y-chain becoming tyrosine phosphorylated and is normally 
only detectable following precipitation using a fusion protein 
containing the SH2 domains of Syk. The position of the mi-
gration in Fig. 2 indicates that the detectable FcR y-chain 
which is co-precipitated with GPVI is not tyrosine phos-
phorylated. 
Reports have demonstrated that platelets can be activated 
by incubation with anti-GPVI antibodies [7,9,21]. This is as-
sociated with an increase in protein tyrosine phosphorylation, 
including several key components of the pathway which is 
activated by collagen. Amongst these is Syk, which we have 
shown to be essential for collagen-mediated activation [5], 
whereupon it binds to tyrosine phosphorylated FcR y-chain 
[4] and becomes phosphorylated and activated. We therefore 
investigated the effect of cross-linking GPVI on the level of 
tyrosine phosphorylation of the FcR y-chain. GPVI cross-
linking studies were performed using F(ab')2 fragments gen-
erated from anti-GPVI IgG to avoid antibody mediated acti-
vation. Anti-GPVI F(ab')2 fragments caused rapid and com-
plete aggregation whereas treatment with the same 
concentration of F(ab')2 fragments prepared from control 
plasma had no effect (Fig. 3i). The level of whole cell protein 
tyrosine phosphorylation in these samples was assessed by 
immunoblotting. The profile of tyrosine phosphorylation in-
duced following cross-linking of GPVI is indistinguishable 
from that of collagen-stimulated platelets; in contrast no sig-
nificant change in the level of tyrosine phosphorylation was 
observed following treatment with the control F(ab')2 (Fig. 
3ii). Arrows indicate the positions of several prominent pro-
teins of approximately 145, 130, 80, 40 and 12 kDa which 
become heavily tyrosine phosphorylated in both collagen-
stimulated and GPVI cross-linked cells. The smallest of these 
proteins migrates on SDS-PAGE under reducing conditions 
to a similar position to tyrosine phosphorylated FcR y-chain. 
To confirm the identity of this protein, tyrosine phosphoryl-
ated FcR y-chain was precipitated from platelets lysates using 
a fusion protein containing the tandem SH2 domains of Syk. 
Precipitated proteins were separated by SDS-PAGE and im-
munoblotted for phosphotyrosine residues. Fig. 3iii shows 
that incubation of platelets with anti-GPVI F(ab')2 induces 
an increase in the level of tyrosine phosphorylation of the 
FcR y-chain resulting in the precipitation of more of the pro-
tein. To check that this increase was not due to whole IgG 
contamination of the anti-GPVI F(ab')2 preparation, the ef-
fect of cross-linking the platelet IgG receptor, FcyRIIA, on 
the level of phosphorylation of the FcR y-chain was examined 
and found to be similar to that following treatment with the 
control F(ab')2 preparation (not shown). This is in accordance 
with our previous findings [4]. 
Our results indicate that GPVI is the signalling collagen 
receptor whose activation results in the tyrosine phosphoryla-
tion of the FcR y-chain. This supports the recent conclusion 
of Polgar et al. [26] who identified a component of the venom 
of the tropical rattlesnake (Crotalus durissus terrificus) which 
binds to GPVI. Exposure of platelets to this C-type lectin 
results in tyrosine phosphorylation of the FcR y-chain 
amongst many other proteins, leading to platelet activation. 
The present results strengthen the proposal that effect of the 
venom is due to its ability to bind and cross-link GPVI. 
The importance of the collagen-stimulated tyrosine kinase-
dependent pathway and its stimulation via GPVI is demon-
strated by the mild bleeding problems observed in patients 
who lack this protein or who express autoantibodies to it 
[7,8,10,22]. Given the potential importance of collagen in 
thrombotic disorders, the receptor described here, or an addi-
tional component of it, may provide an important target in 
the development of anti-thrombotic drugs. GPVI is the first 
example of a non-Fc receptor to couple to the FcR y-chain. 
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